Andrea S. Kim, PhD, MBA, DABT

Andrea S. Kim, PhD, MBA, DABT has over 18 years of experience in the pharmaceutical and biotechnology industries. Andrea S. began their career in 2002 as a Postdoctoral Associate at the Fred Hutchinson Cancer Research Center. Andrea S. then moved to the Samsung Advanced Institute of Technology as a Research Scientist in 2003. In 2004, they became a Postdoctoral Fellow at the US EPA. In 2006, they joined Allergan as a Principal Scientist/Senior Scientist/Scientist, Toxicology. In 2014, they were appointed as Director/Associate Director, Nonclinical Safety Assessment at Theravance Biopharma, Inc. In 2017, they became Director, Preclinical Development at RAPT Therapeutics. In 2018, they were appointed Senior Director/Director, Toxicology at Global Blood Therapeutics. Currently, they are the Executive Director, Nonclinical Development at Evommune.

Andrea S. Kim, PhD, MBA, DABT received their Bachelor of Science in Biochemistry from Western Washington University in 1994. Andrea S. then completed their PhD in Toxicology from the Massachusetts Institute of Technology in 2001. In 2007, they earned their MBA from the University of California, Irvine - The Paul Merage School of Business. In 2012, they obtained the DABT certification from the American Board of Toxicology.